umeclidinium 62.5 µg and vilanterol 25 µg + Revefenacin 175 µg, Formoterol 20 µg + Placebo ( Revefenacin and Formoterol ) + Placebo DPI
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
COPD (Chronic Obstructive Pulmonary Disease)
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Trial Timeline
Dec 5, 2023 → Dec 1, 2025
NCT ID
NCT07133880About umeclidinium 62.5 µg and vilanterol 25 µg + Revefenacin 175 µg, Formoterol 20 µg + Placebo ( Revefenacin and Formoterol ) + Placebo DPI
umeclidinium 62.5 µg and vilanterol 25 µg + Revefenacin 175 µg, Formoterol 20 µg + Placebo ( Revefenacin and Formoterol ) + Placebo DPI is a approved stage product being developed by Theravance Biopharma for COPD (Chronic Obstructive Pulmonary Disease). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07133880. Target conditions include COPD (Chronic Obstructive Pulmonary Disease).
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07133880 | Approved | Recruiting |
Competing Products
20 competing products in COPD (Chronic Obstructive Pulmonary Disease)